Klin Farmakol Farm. 2015;29(2):57-61

Novel treatment of symptomatic metastatic or locally advanced basal cell carcinoma unsuitable

Lucie Růžičková Jarešová

Dermatovenerologie, Nemocnice na Homolce, Praha

for surgical treatment of radiotherapy

Basal cell carcinoma (basalioma, BCC) is the most frequent non-melanoma skin cancer, with a high incidence, but a low mortality rate. It is

locally aggressive, with advanced tumours being capable of significantly destroying the surrounding tissue; however, metastases are very

rare. The treatment of BCC depends on the tumour size and type. Surgical treatment is the most common choice. Other options include

the administration of liquid nitrogen (cryodestruction) or the administration of imiquimod (Aldara cream). In extensive and destructive

foci, Erivedge biological therapy is currently available. It is registered by the European Medicines Agency, with the active ingredient

vismodegib. It is the first inhibitor of the Hedgehog signalling pathway in a tablet form. The dosage is 150 mg once daily. Vismodegib

is thus an oral inhibitor of the Hedgehog signalling pathway. Registration was approved based on the phase II Erivance clinical trial.

Keywords: basal cell carcinoma, Hedgehog pathway, vismodegib

Published: July 1, 2015  Show citation